Stroke (Hoboken, N.J.) · 2023
Post-Market Registry of Stroke Patients Treated With Medtronic Neurothrombectomy Devices in Southeast Asia: PROSPR-SEA.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Huy Thang, Ton Mai Duy, Vu Dang Luu, Churojana Anchalee, Nilanont Yongchai, Ayudya Sirintara Pongpech Singhara Na, De Silva Deidre Anne, Hoe Winston Lim Eng, Van Truong Le, Pham Minh Thong, Worakijthamrongchai Thanaboon, Tran Quoc Tuan, Seet Raymond Chee Seong, Lee Wickly
Аннотация
BACKGROUND: Southeast Asia accounts for approximately 10% of stroke-related mortalities worldwide, yet there are limited data regarding mechanical thrombectomy (MT) outcomes in this region. PROSPR-SEA (Post-Market Registry of Stroke Patients Treated With Medtronic Neurothrombectomy Devices to Collect Real-World Data in Southeast Asia) assessed post-market clinical outcomes of MT using the Solitaire Revascularization Device in southeast Asia.
METHODS: PROSPR-SEA is a prospective, multicenter, nonrandomized, observational registry of patients who underwent MT using Solitaire as first line treatment at 1 of 10 centers in Vietnam, Thailand, and Singapore between January 2018 and July 2019. The primary end point was functional independence (modified Rankin scale 0-2) at 90 days. Safety end points included symptomatic intracerebral hemorrhage, emboli in new territory at 24 hours, and all-cause mortality at 90 days. Secondary end points were successful revascularization (modified thrombolysis in cerebral infarction ≥2b), workflow metrics, National Institutes of Health Stroke Scale score at discharge, and patient disposition at 90 days.
RESULTS: A total of 183 patients (64.9±13.7, 49.7% [91/183] female) were included in the study and underwent MT; 79.2% (145/183) had occlusions in the middle cerebral artery. Median baseline National Institutes of Health Stroke Scale was 15.0 (range 1-31) and median baseline Alberta Stroke Program Early CT Score was 8.0 (range 0-10). Functional independence at 90 days was achieved in 62.2% (112/180). Mean puncture-to-revascularization time was 53.3±53.9 minutes, and mean onset-to-revascularization time was 330.0±110.4 minutes. Revascularization was successful in 94.0% (172/183) of patients. Median National Institutes of Health Stroke Scale improved at discharge (-8.0, range -22, 25) and 90 days (-13.0, range -22, 0). Within 24 hours, symptomatic intracerebral hemorrhage occurred in 7.7% (14/183) and emboli in new territory in 3.3% (6/183). At 90 days, the all-cause mortality rate was 7.7% (14/183). Most patients were discharged to home by 90 days (84.1%, 154/183).
CONCLUSION: PROSPR-SEA demonstrated high rates of positive functional outcomes and procedural success with a low mortality rate and indicates that the technical and clinical outcomes of landmark MT trials using Solitaire as the first-line device are reproducible in real-world southeast Asian settings.
METHODS: PROSPR-SEA is a prospective, multicenter, nonrandomized, observational registry of patients who underwent MT using Solitaire as first line treatment at 1 of 10 centers in Vietnam, Thailand, and Singapore between January 2018 and July 2019. The primary end point was functional independence (modified Rankin scale 0-2) at 90 days. Safety end points included symptomatic intracerebral hemorrhage, emboli in new territory at 24 hours, and all-cause mortality at 90 days. Secondary end points were successful revascularization (modified thrombolysis in cerebral infarction ≥2b), workflow metrics, National Institutes of Health Stroke Scale score at discharge, and patient disposition at 90 days.
RESULTS: A total of 183 patients (64.9±13.7, 49.7% [91/183] female) were included in the study and underwent MT; 79.2% (145/183) had occlusions in the middle cerebral artery. Median baseline National Institutes of Health Stroke Scale was 15.0 (range 1-31) and median baseline Alberta Stroke Program Early CT Score was 8.0 (range 0-10). Functional independence at 90 days was achieved in 62.2% (112/180). Mean puncture-to-revascularization time was 53.3±53.9 minutes, and mean onset-to-revascularization time was 330.0±110.4 minutes. Revascularization was successful in 94.0% (172/183) of patients. Median National Institutes of Health Stroke Scale improved at discharge (-8.0, range -22, 25) and 90 days (-13.0, range -22, 0). Within 24 hours, symptomatic intracerebral hemorrhage occurred in 7.7% (14/183) and emboli in new territory in 3.3% (6/183). At 90 days, the all-cause mortality rate was 7.7% (14/183). Most patients were discharged to home by 90 days (84.1%, 154/183).
CONCLUSION: PROSPR-SEA demonstrated high rates of positive functional outcomes and procedural success with a low mortality rate and indicates that the technical and clinical outcomes of landmark MT trials using Solitaire as the first-line device are reproducible in real-world southeast Asian settings.